Validity of the QUADAS-2 in Assessing Risk of Bias in Alzheimer's Disease Diagnostic Accuracy Studies

Accurate detection of Alzheimer's disease (AD) is of considerable clinical importance. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) is the current research standard for evaluating the quality of studies that validate diagnostic tests; however, its own construct validity has not yet been evaluated empirically. Our aim was to evaluate how well the proposed QUADAS-2 items and its domains converge to indicate the study quality criteria. This study applies confirmatory factor analysis to determine whether a measurement model would be consistent with meta-analytic data. Cochrane meta-analyses assessing the accuracy of AD diagnostic tests were identified. The seven ordinal QUADAS-2 items, intended to inform study quality based on risk of bias and applicability concerns, were extracted for each of the included studies. The QUADAS-2 pre-specified factor structure (i.e., four domains assessed in terms of risk of bias and applicability concerns) was not testable. An alternative model based on two correlated factors (i.e., risk of bias and applicability concerns) returned a poor fit model. Poor factor loadings were obtained, indicating that we cannot provide evidence that the indicators convergent validity markers in the context of AD diagnostic accuracy metanalyses, where normally the sample size is low (around 60 primary included studies). A Monte Carlo simulation suggested that such a model would require at least 90 primary studies to estimate these parameters with 80% power. The reliability of the QUADAS-2 items to inform a measurement model for study quality remains unconfirmed. Considerations for conceptualizing such a tool are discussed.

[1]  P. Bossuyt,et al.  BMC Medical Research Methodology , 2002 .

[2]  Daniel Rueckert,et al.  Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment , 2013, Neurobiology of Aging.

[3]  Hanna Cho,et al.  Tau PET in Alzheimer disease and mild cognitive impairment , 2016, Neurology.

[4]  Norman Crolee Dalkey,et al.  An experimental study of group opinion , 1969 .

[5]  N. Dendukuri,et al.  Quality and Reporting of Diagnostic Accuracy Studies in TB, HIV and Malaria: Evaluation Using QUADAS and STARD Standards , 2009, PloS one.

[6]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[7]  T Raykov,et al.  Scale Reliability, Cronbach's Coefficient Alpha, and Violations of Essential Tau-Equivalence with Fixed Congeneric Components. , 1997, Multivariate behavioral research.

[8]  Tihomir Asparouhov,et al.  Sampling Weights in Latent Variable Modeling , 2005 .

[9]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[10]  Robert J. Vokurka,et al.  The empirical assessment of construct validity , 1998 .

[11]  K. Nie,et al.  Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis , 2015, The International journal of neuroscience.

[12]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[13]  Jacob Cohen Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[14]  Yemisi Takwoingi,et al.  (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). , 2014, The Cochrane database of systematic reviews.

[15]  A. Fagan,et al.  Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. , 2016, JAMA neurology.

[16]  J. Sepulcre,et al.  Advanced Neuroimaging Methods Towards Characterization of Early Stages of Alzheimer's Disease. , 2016, Methods in molecular biology.

[17]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[18]  Carol Brayne,et al.  Montreal Cognitive Assessment for the diagnosis of Alzheimer's disease and other dementias. , 2015, The Cochrane database of systematic reviews.

[19]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[20]  S. Black,et al.  Beyond the hippocampus , 2001, Neurology.

[21]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[22]  Phil Wood Confirmatory Factor Analysis for Applied Research , 2008 .

[23]  C. Sudlow,et al.  Accuracy of Electronic Health Record Data for Identifying Stroke Cases in Large-Scale Epidemiological Studies: A Systematic Review from the UK Biobank Stroke Outcomes Group , 2015, PloS one.

[24]  B. Muthén,et al.  How to Use a Monte Carlo Study to Decide on Sample Size and Determine Power , 2002 .

[25]  J. Ioannidis,et al.  Can quality of clinical trials and meta-analyses be quantified? , 1998, The Lancet.

[26]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[27]  Denny Borsboom,et al.  Frontiers of Test Validity Theory: Measurement, Causation, and Meaning , 2013 .

[28]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[29]  Chris Hyde,et al.  Neuropsychological tests for the diagnosis of Alzheimer's disease dementia and other dementias: a generic protocol for cross-sectional and delayed-verification studies. , 2013, The Cochrane database of systematic reviews.

[30]  G. Freytag [CORRELATION AND CAUSALITY]. , 1964, Psychiatrie, Neurologie, und medizinische Psychologie.

[31]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[32]  Sandra E Black,et al.  Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome , 2013, Alzheimer's Research & Therapy.

[33]  M. Dewey,et al.  The Revised QUADAS-2 Tool , 2012, Annals of Internal Medicine.

[34]  K. Blennow,et al.  CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis , 2016, The Lancet Neurology.

[35]  Yannis Pappas,et al.  Signs and symptoms preceding the diagnosis of Alzheimer’s disease: a systematic scoping review of literature from 1937 to 2016 , 2017, BMJ Open.

[36]  C. Sudlow,et al.  Accuracy of Patient Self-Report of Stroke: A Systematic Review from the UK Biobank Stroke Outcomes Group , 2015, PloS one.

[37]  Ingrid Arevalo-Rodriguez,et al.  Diagnostic tools for alzheimer’s disease dementia and other dementias: an overview of diagnostic test accuracy (DTA) systematic reviews , 2014, BMC Neurology.

[38]  J. Sterne,et al.  Is MRI better than CT for detecting a vascular component to dementia? A systematic review and meta-analysis , 2012, BMC Neurology.

[39]  Andreas Ritter,et al.  Structural Equations With Latent Variables , 2016 .

[40]  A. Hammers,et al.  Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease , 2016 .

[41]  J. Cleland,et al.  The creation of the diagnostic accuracy quality scale (DAQS) , 2014, The Journal of manual & manipulative therapy.

[42]  Rick H Hoyle,et al.  Reporting Results from Structural Equation Modeling Analyses in Archives of Scientific Psychology. , 2013, Archives of scientific psychology.

[43]  Francesco Brigo,et al.  123I-FP-CIT SPECT in the differential diagnosis between dementia with Lewy bodies and other dementias , 2015, Journal of the Neurological Sciences.

[44]  Craig Ritchie,et al.  Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). , 2014, The Cochrane database of systematic reviews.

[45]  D. Rennie,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative , 2003, BMJ : British Medical Journal.

[46]  K. Jöreskog Statistical analysis of sets of congeneric tests , 1971 .

[47]  Philip Scheltens,et al.  Imaging in Alzheimer's disease , 2009, Dialogues in clinical neuroscience.

[48]  H W Marsh,et al.  Is More Ever Too Much? The Number of Indicators per Factor in Confirmatory Factor Analysis. , 1998, Multivariate behavioral research.

[49]  P. Bentler,et al.  Formative Constructs Implemented via Common Factors , 2011 .

[50]  Kenneth A. Bollen,et al.  Causal Indicator Models: Identification, Estimation, and Testing , 2009 .

[51]  P. A. van den Brandt,et al.  The art of quality assessment of RCTs included in systematic reviews. , 2001, Journal of clinical epidemiology.

[52]  M. Turner,et al.  Maternal body mass index and the prevalence of spontaneous and elective preterm deliveries in an Irish obstetric population: a retrospective cohort study , 2017, BMJ Open.

[53]  Tihomir Asparouhov,et al.  General Multi-Level Modeling with Sampling Weights , 2006 .

[54]  Rex B. Kline,et al.  Principles and Practice of Structural Equation Modeling , 1998 .

[55]  D. Moher,et al.  Guidance for Developers of Health Research Reporting Guidelines , 2010, PLoS medicine.

[56]  André Beauducel,et al.  On the Performance of Maximum Likelihood Versus Means and Variance Adjusted Weighted Least Squares Estimation in CFA , 2006 .

[57]  H. Marsh,et al.  In Search of Golden Rules: Comment on Hypothesis-Testing Approaches to Setting Cutoff Values for Fit Indexes and Dangers in Overgeneralizing Hu and Bentler's (1999) Findings , 2004 .